Khiron CEO to Participate at ATB 9th Annual Institutional Investor Conference

TORONTO, Jan. 8, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will participate live at the ATB 9th Annual Institutional Investor Conference  being held on January 12-14, 2021 .

Mr. Torres is scheduled to participate in a panel on Thursday, January 14, 2021 at 3:40pm ET as well as host one-on-one investor meetings throughout the day.

Date: Thursday, January 14, 2021
Time: International cannabis panel 3:40pm ET
To attend the event visit:

Recent Khiron Highlights

  • First company in Colombia to export THC products with shipments to Peru 
  • Appoints former Colombia Minister of Finance Juan Carlos Echeverry as an independent member of its Board of Directors 
  • Opens new, small-format clinic in Medellin, Colombia's 2nd largest city, extending Company's LatAm clinic network
  • Declared a National Strategic Project by the Government of Colombia, accelerating administration processes for the Company's strategic initiatives 
  • Doctor ZereniaTM telehealth platform attracts 25% of patients from outside of Bogota, expanding national reach 
  • Colombian government extends medical health insurance coverage to THC and CBD medical cannabis products 

About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products. The Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence sales of medical cannabis in Germany and Brazil in early 2021.

Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with KuidaTM now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Cision View original content to download multimedia:

SOURCE Khiron Life Sciences Corp.